Qingyan Bo

Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial

Man‐Fung Yuen, Xue Zhou, Edward Gane et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 57 citations

Hepatology, Viral Hepatitis, Antiviral Activity +8

Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B

Jinlin Hou, Wenhong Zhang, Qing Xie et al. · New England Journal of Medicine · 2024 · 55 citations · Full text

What drives the dynamics of HBV RNA during treatment?

António Gonçalves, Annabelle Lemenuel‐Diot, Valérie Cosson et al. · Journal of Viral Hepatitis · 2020 · 26 citations

RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated

Edward Gane, A. Liu, MF Yuen et al. · Journal of Hepatology · 2018 · 24 citations

Hepatology, Viral Hepatitis, Immunology +8

A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants

Sheng Feng, Edward Gane, Christian Schwabe et al. · Antimicrobial Agents and Chemotherapy · 2020 · 22 citations · Full text